Tobacco treatment specialist
Colin Mendelsohn has written
to the Australian Prescriber
highlighting the paradoxically
enhanced response smokers have
to the antiplatelet drug clopidogrel.
The so-called “smokers’ paradox”
was brought to light in a recent
meta-analysis showing that the
clinical benefit of clopidogrel in
reducing cardiovascular events was
seen primarily in smokers (25% risk
reduction compared to controls),
with little benefit in non-smokers
(8% reduction), but failed to get a
mention in the publication’s recent
review of new antiplatelet drugs.
Mendelsohn sought clarification
on dosing implications of these
issues - CLICK HERE for more.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Aug 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Aug 15
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.